Paris-based MSInsight Raises €1.6 Mn To Redefine MSI Cancer Diagnosis

The investment will fuel the development and regulatory approval of MSIcare, its AI-powered diagnostic software designed to improve the accuracy of detecting microsatellite instability (MSI) cancers.

With this funding, MSInsight is advancing its goal of making accurate MSI diagnostics widely available, reducing misdiagnoses, and ensuring cancer patients get the best treatment.

The round was led by Calyseed, with participation from Plateau de Saclay Business Angels, Yes Invest, Capital Cell and banking support from bpifrance.

Read more - Mimo funding news – London-based Mimo Secures $8.5Million in funding.

“This fundraising marks a key milestone for MSInsight. It gives us the means to accelerate the deployment of our technology and strengthen our clinical partnerships. We have already proven that our approach outperforms current methods in several types of cancer. Thanks to this funding, we are preparing the CE-IVD certification procedures for MSIcare.

“The company’s ambition is to position its MSIcare solution as the future gold standard for assessing microsatellite instability and the first regulatory – valida ted bioinformatics solution,” said Arnaud Cutivet, PhD, president and Co-founder of MSInsight.

“MSIcare has the potential to become a standard in oncology diagnostics, significantly improving the therapeutic orientation and care pathway. We strongly believe in this solution, which is part of an evolving trend of using NGS sequencing tests to diagnose and use MSI biomarkers in oncology. The bioinformatics software developed can be easily integrated into laboratory practices.

Also read - Northbound & VIZION: Reducing D&D with Real-Time Visibility.

“MSInsight’s innovation has already demonstrated its performance and reliability in retrospective studies. The startup benefits from intellectual rights, an expert team, and a network of quality partners that should make it possible to reach the key milestones for the next round of funding,” said Elodie Panier, Managing Director of Calyseed.

“Capital Cell is thrilled to have directed significant funding from more than 170 investors to MSInsight, a company that demonstrates immense potential in the field of cancer care,” said Daniel Oliver, Director of Capital Cell.

MSIcare, the startup’s key innovation, improves cancer diagnosis by addressing the shortcomings of current methods, which can be inaccurate in up to 30% of cases. By enhancing MSI biomarker detection, it helps ensure that more patients receive the right treatment, especially immunotherapy, which significantly boosts survival rates.

MSI cancers affect nearly one million people worldwide each year, mainly in the digestive and gynecological systems. Since the MSI biomarker is crucial for determining whether immunotherapy is suitable, accurate detection is essential. However, current diagnostic methods often lead to misdiagnoses, incorrect treatments, and unnecessary healthcare costs.

The company also plans to expand its technology to pediatric oncology and hereditary cancer screening, including detecting Lynch syndrome, a common genetic condition linked to cancer risk.